TrialCompass™ TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT04496349

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is comparing APG-115 and APG-2575 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

APG-115 (DRUG): QOD, 2 weeks on, 1 week off, in repeated 21-day cycles | APG-2575 (DRUG): APG-2575 given orally each day in cycle, in repeated 21-day cycles

Drugs / treatments
APG-115, APG-2575
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

NCT04496349

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is comparing APG-115 and APG-2575 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

APG-115 (DRUG): QOD, 2 weeks on, 1 week off, in repeated 21-day cycles | APG-2575 (DRUG): APG-2575 given orally each day in cycle, in repeated 21-day cycles

Drugs / treatments: APG-115, APG-2575

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 78 patients

Primary endpoint: Maximum tolerated dose of APG-115; Maximum tolerated dose of APG-115+APG-2575

Ages: 18 Years to —

Start date: 2021-07-12 | Est. completion: 2027-05-31

Locations

1 US sites · 1 total

Texas

Contact

Genevieve Frank | genevieve.frank@ascentage.com | 301-802-3659

Sponsor: Ascentage Pharma Group Inc. (INDUSTRY)

Tags

T-PLL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04496349

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.